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Abstract
Obesity is an important risk factor for severe asthma exacerbations, which are mainly caused by 
respiratory infections. Dietary fatty acids, which are increased systemically in obese patients and are 
further increased after high fat meals, affect the innate immune system and may contribute to 
dysfunctional immune responses to respiratory infection. This study investigated the effects of 
dietary fatty acids on immune responses to respiratory infection in pulmonary fibroblasts and a 
bronchial epithelial cell line (BEAS-2B). 
Cells were challenged with BSA-conjugated fatty acids (ω-6 PUFAs, ω-3 PUFAs or SFAs) +/- the viral 
mimic polyinosinic:polycytidylic acid (PolyI:C) or bacterial compound lipoteichoic acid (LTA) and 
release of pro-inflammatory cytokines was measured. In both cell types, challenge with arachidonic 
acid (AA) (ω-6 PUFA) and PolyI:C or LTA led to substantially greater IL-6 and CXCL8 release than 
either challenge alone, demonstrating synergy. In epithelial cells, palmitic acid (SFA) combined with 
PolyI:C also led to greater IL-6 release. The underlying signaling pathways of AA and PolyI:C -or LTA-
induced cytokine release were examined using specific signaling inhibitors and immunoblotting. 
Cytokine production in pulmonary fibroblasts was prostaglandin-dependent, and synergistic 
upregulation occurred via p38 MAP kinase signaling, whereas cytokine production in BEAS2Bs was 
mainly mediated through JNK and p38 MAPK signaling. We confirmed these findings using rhinovirus 
infection, demonstrating that AA enhances rhinovirus-induced cytokine release. 
This study suggests that during respiratory infection, increased levels of dietary ω-6 PUFAs and SFAs 
may lead to more severe airway inflammation and may contribute to and/or increase the severity of 
asthma exacerbations.
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Introduction
More than two billion people around the world are overweight or obese with a body mass index 
(BMI) of 25kg/m2 or more (1). This global epidemic is associated with many chronic diseases, 
including asthma. A number of epidemiological studies show that obesity is an important risk factor 
for asthma development, increasing the risk by 2.7 fold compared to normal body weight (2). 
However, the underlying mechanisms are still poorly understood. 
Clinical studies suggest that asthma in obese individuals differs from the classical phenotype of the 
disease. The obese asthma phenotype is characterized by greater severity, poorer control and 
quality of life, and lack of atopy with neutrophilic inflammation being specifically reported in obese 
women (2-5). Obesity also increases the risk of exacerbations and obese patients are almost five 
times more likely to be hospitalised for asthma exacerbations, compared to lean patients (3, 6, 7). 
Higher BMI appears to particularly increase the risk of autumn/winter exacerbations in more severe 
forms of asthma (6). 
The major cause of asthma exacerbations is respiratory infection with rhinovirus (RV) accounting for 
up to 80% of all exacerbations (8). Viral-induced exacerbations in asthma are associated with 
increased levels of interleukin (IL)-6, the neutrophil chemoattractant CXCL8 and neutrophilic 
inflammation (9, 10). There are some studies that have reported bacterial infection to also be 
related to asthma exacerbations (11, 12), however this relationship is less evident. The impact of 
obesity on immune responses to infections is not clear, however obesity is associated with more 
severe outcomes following respiratory infection (13, 14). Several studies have shown associations 
between obesity and hospitalization and mortality following infection with pandemic influenza 
A/H1N1 in 2009 (15, 16). A recent study by Campitelli et al. (2014) showed that obesity increases the 
risk of outpatient visits following respiratory infection, compared to a normal body weight (14). 
The innate immune system is the first line of defence against pathogens and its aim is to rapidly clear 
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the body of pathogens. To do so, the innate immune system triggers an immediate inflammatory 
response that induces migration and activation of immune cells into infected sites. However, an 
excessive inflammatory response may induce greater tissue damage than that caused by pathogens 
and can contribute to the cause and severity of exacerbations (8). 
Obesity is the result of the continuous overconsumption of nutrients. The western diet contributes 
to obesity, being rich in saturated- (SFA) and ω-6 polyunsaturated fatty acids (PUFAs) and low in ω-3 
PUFAs (17). It has been shown that the consumption of high fat meals leads to increased levels of 
circulating fatty acids and modulates the innate immune system, as shown by increases in the levels 
of CXCL8 as well as the proportion of neutrophils in the circulation and sputum (18, 19). Obesity 
itself is also associated with increased fatty acid levels (20). The serum levels of SFAs and ω-6 PUFAs 
are substantially higher than ω-3 PUFAs (21-23). ω-6 PUFAs and SFAs have predominantly been 
associated with pro-inflammatory effects and current evidence suggests that SFAs promote 
inflammation through the activation of a family of receptors involved in innate immunity, known as 
Toll-like receptors (TLRs) (24). Several studies suggest that ω-3 PUFAs have anti-inflammatory and 
immunosuppressive properties and may be beneficial in treating infectious diseases. ω-3 and ω-6 
PUFAs act as bio-active molecules that are metabolized by cyclooxygenase (COX) and lipoxygenase 
(LOX) into prostaglandins and leukotrienes respectively, which have potential anti- and pro-
inflammatory actions of their own (25).
An emerging hypothesis to explain why obese patients have more frequent and severe asthma 
exacerbations is dysfunctional innate immune responses to viral and/or bacterial respiratory 
infections. Increased levels of dietary fatty acids could potentially contribute to these dysfunctional 
immune responses.
The bronchial epithelium has always been considered as the primary site of infection. However, in 
vivo evidence shows infection also occurs in submucosal cells including pulmonary fibroblasts (26). 
This study investigated the effect of dietary fatty acids on primary human pulmonary fibroblasts 
(HPFs) and a bronchial epithelial cell line (BEAS-2B) in vitro, specifically examining the possible 
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enhancement of respiratory infection through measuring release of inflammatory mediators 
involved in immune responses against infection. 
Methods
Cell culture 
HPFs were isolated from the parenchyma of lungs from patients undergoing lung transplantation or 
lung resection for thoracic malignancies, as previously described (27). Ethical approval for all 
experiments involving the use of human lung tissue was provided by the Sydney South West Area 
Health Service, and written informed consent was obtained. Table 1 shows the patient 
demographics. We also used the bronchial cell line BEAS-2B (ATCC, Manassas, VA). Detailed methods 
for culture of HPFs and BEAS2B are provided in the Online Supplements. 
Preparation of BSA-conjugated fatty acids
Stock solutions of 0.5M ω-3 polyunsaturated fatty acids (PUFAs) (docosahexaenoic acid (DHA), 
eicosapentaenoic acid (EPA) and α-Linolenic acid (ALA)), saturated fatty acid (SFA) (palmitic acid 
(PA)) and 0.3M ω-6 PUFA (arachidonic acid (AA)) (Sigma Aldrich) were prepared in 100% EtOH and 
stored at -20°C. Working water-soluble solutions of 10mM were generated by incubating the fatty 
acids in 10% endotoxin and fatty acid-free BSA (Sigma Aldrich), as previously described by Gupta et 
al. (2012) (28). 
Treatment of cells 
The cells were challenged with DHA, EPA, ALA, PA or AA (100µM) or vehicle (EtOH/BSA/cell culture 
medium) 4 hours prior to stimulation with or without the viral mimic polyinosinic:polycytidylic acid 
(PolyI:C) (10μg/ml) or bacterial compound lipoteichoic acid (LTA) (10µg/ml)(Sigma Aldrich). All cells 
were incubated at 37°C with 5% CO2 for 24 hours. 
Determination of IL-6,CXCL8, GM-CSF and CCL5 levels
Levels of supernatant IL-6, CXCL8, granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
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chemokine (C-C motif) ligand 5 (CCL5) were measured using commercial ELISA kits according to the 
manufacturer’s instructions (R&D Systems, Minnesota, USA). 
Western blotting 
Total protein concentrations were obtained using a bicinchoninic acid assay according to the 
manufacturer’s instructions (Sigma-Aldrich). Cell lysates (10µg) were separated by SDS-PAGE on 10% 
gels and transferred to PVDF membranes. The membranes were incubated with rabbit monoclonal 
antibodies against total and phosphorylated NF-κB p65, p38 mitogen-activated protein kinase 
(MAPK) or stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) (all 1:1000, Cell 
Signaling Technology) and anti-mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(1:5000, Merck Millipore, USA). Primary antibodies were detected with goat anti-rabbit or rabbit 
anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibodies (DAKO, USA) and 
visualized by enhanced chemiluminescence (Image Station 4000MM; Kodak Digital Science, New 
Haven, CT). GAPDH served as the loading control. Detailed methods are provided in the Online 
Supplements.
Signaling pathway inhibition
HPFs and BEAS-2Bs were treated with inhibitors of p38 MAPK (SB239063, 3µM, IC50 = 44nM) (Tocris, 
Ellisville, MO, USA), JNK (SP600125, 10µM, IC50 = 40 nM for JNK-1 and 2 and 90 nM for JNK-3) 
(Calbiochem, San Diego, CA), COX (indomethacin, 10µM, IC50 = 0.23µM for COX-1 and IC50 = 0.63 µM 
for COX-2) (Sigma) and NF-κB (BAY-117082, 10µM, IC50 = 10µM) (Sigma) for 1 hour before 
stimulation with AA (100µM) with or without PolyI:C (10µg/mL) or LTA (10µg/mL).
Rhinovirus infection 
Major group human RV serotype-16 (RV16) was a kind gift from Prof Johnston (imperial College UK). 
RV16 was grown in HeLa cells and infectivity titre was determined using a titration assay as 
previously described (29, 30). HPFs were unstimulated or treated with AA (100µM) 4 hours prior to 
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infection with or without live RV16 at a multiplicity of infection (MOI) of 1. Plates were incubated at 
37°C with 5% CO2 for 24 hours. 
Statistical analysis
Statistical analysis was conducted using GraphPad Prism version 7 software (San Diego, CA). 
Comparisons of the data were carried out by one-way ANOVA with repeated measures followed by a 
Bonferroni post-test, where appropriate unless otherwise specified. A probability (p) value of less 
than 0.05 was considered significant.
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Results 
Stimulation with AA and PolyI:C leads to greater cytokine release from fibroblasts. 
To assess if dietary fatty acids modulate the response to viral infection, HPFs were challenged with 
100µM of DHA, PA or AA prior to stimulation with PolyI:C (10µg/ml) and IL-6, CXCL8, GM-CSF and 
CCL5 release was measured. AA alone, but not DHA or PA, induced IL-6 and CXCL8 release (n = 11, 
p<0.05) (Figure 1). PolyI:C alone also induced IL-6 and CXCL8 release (n = 11, p<0.05). Challenge with 
the combination of AA and PolyI:C resulted in substantially greater IL-6 and CXCL8 release than AA 
alone (n = 11, p<0.01) (Figure 1A and 1B). The effect of the combination of AA with PolyI:C on IL-6 
and CXCL8 release was greater than the sum of the individual effects of AA and PolyI:C, 
demonstrating a synergistic effect. There was no interaction between DHA or PA and PolyI:C on IL-6 
and CXCL8 release. None of the treatments induced GM-CSF release from the HPFs (data not 
shown). CCL5 was induced upon PolyI:C -challenge and interestingly AA and DHA suppressed PolyI:C-
induced CCL5 release (n = 5-8, p<0.05) (Figure 1C and 1F).   
Stimulation with AA and LTA leads to greater cytokine release from fibroblasts. 
To evaluate whether there is an interaction between dietary fatty acids and bacterial infection, HPFs 
were treated with dietary fatty acids prior to stimulation with LTA (10µg/ml). LTA alone did not 
induce IL-6 or CXCL8 release (Figure 2). However, both IL-6 and CXCL8 release (n = 11, p<0.05) was 
greater upon challenge with the combination of AA and LTA compared to AA alone (Figure 2A and 
2B), also demonstrating synergistic effects. Again, there was no interaction between DHA or PA and 
LTA. In addition, there was no induction of GM-CSF or CCL5 with any of these treatments (data not 
shown). 
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ω-3 PUFAs do not suppress combined AA and PolyI:C-induced cytokine release. 
The ω-3 PUFA DHA did not affect PolyI:C -induced IL-6 and CXCL8 release in HPFs. To confirm that 
ω-3 PUFAs do not affect IL-6 and CXCL8 release, we investigated the effects of the other ω-3 PUFAs 
ALA and EPA and found that these fatty acids also do not affect the response to PolyI:C (See 
Supplementary Figure 1). Because nutrients do not occur in isolation, and healthy diet consists of 
ω-3 PUFAs:ω-6 PUFAs in a 1:4 ratio (31), we next investigated the effects of DHA:AA, EPA:AA and 
ALA:AA in a 1:4 ratio on PolyI:C-induced cytokine release. There was no difference in the response to 
AA with or without DHA, EPA or ALA in combination with PolyI:C (See Supplementary Figure 2), 
showing that ω-3 PUFAs do not suppress AA and PolyI:C mediated inflammatory responses in HPFs.  
Stimulation with AA and PolyI:C or LTA also leads to greater cytokine release from epithelial cells. 
To explore whether other structural lung cells respond similarly to HPFs, we repeated selected 
experiments in the bronchial epithelial cell line, BEAS-2B. AA alone did not induce IL-6 or CXCL8 
release from BEAS-2Bs, however AA in combination with PolyI:C resulted in greater IL-6 release 
(n = 6, p<0.05) than PolyI:C alone (Figure 3A), showing similar responses as in HPFs. PA in 
combination with PolyI:C also resulted in greater IL-6 release (n = 6, p<0.05) than PolyI:C alone 
(Figure 3G). DHA did not affect PolyI:C -induced IL-6 or CXCL8 release, but suppressed PolyI:C-
induced CCL5 release (n = 7, p<0.05) (Figure 3F). Furthermore, LTA alone did not induce cytokine 
release from BEAS-2BS. However, the combination of AA and LTA resulted in significant IL-6 and 
CXCL8 release (n = 6, p<0.01) (Figure 4A and 4B). There was no interaction between DHA or PA and 
LTA (Figure 4C-F).
p38 MAP kinase hyperactivation in pulmonary fibroblasts upon challenge with AA and PolyI:C
To investigate the mechanisms underlying the effects of AA- and combined AA and PolyI:C or LTA-
induced IL-6 and CXCL8 release in HPFs, we used protein immunoblotting to investigate the 
activation of three main signaling pathways (p38, NF-κB and SAPK/JNK), all of which have been 
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shown to play a role in prostaglandin or infection-mediated inflammatory responses (32, 33). 
Phosphorylation of p38 MAP kinase was increased after stimulation with AA alone (n = 8, p<0.01) 
and in combination with PolyI:C (p<0.001) or LTA (p<0.01), while PolyI:C and LTA alone did not affect 
p38 MAP kinase phosphorylation (Figure 5A). The combination of AA and PolyI:C led to greater 
phosphorylation of p38 MAP kinase than AA alone (n = 8, p<0.05), indicating hyperactivation of this 
pathway to be the mechanism by which synergism occurs. NF-κB phosphorylation was increased 
upon challenge with PolyI:C (n = 8, p<0.01) and LTA alone (n = 8, p<0.01), but not in combination 
with AA (Figure 5B). Phosphorylation of SAPK/JNK was increased upon challenge with AA in 
combination with PolyI:C (n = 7, p<0.05), but not with any other challenge (Figure 5C). Total p38 
MAP kinase, NF-κB and SAPK/JNK did not change with any treatment (Figure 5D-F). 
AA and PolyI:C or LTA-induced cytokine release in pulmonary fibroblasts is mediated via p38 MAP 
kinase signaling. To further investigate and confirm the mechanisms underlying the effects of AA- 
and combined AA and PolyI:C- or LTA-induced IL-6 and CXCL8 release, specific inhibitors were used 
to block p38 MAPK, JNK and NF-κB activation. Inhibition of p38 MAP kinase suppressed IL-6 and 
CXCL8 (n = 9-14, p<0.01) release induced by AA alone (Figure 6A and 6B), the combinations of AA 
and PolyI:C (Figure 6E and 6F) and AA and LTA (Figure 6G and 6H), but did not affect cytokine release 
induced by PolyI:C alone. Inhibition of JNK attenuated IL-6 release induced by PolyI:C alone (n = 10, 
p<0.0001) (Figure 6C) and AA combined with PolyI:C (n = 10, p<0.01) (Figure 6E). Inhibition of NF-κB 
only suppressed IL-6 release induced by AA in combination with LTA (n = 14, p<0.01) (Figure 6G).
Inhibition of COX suppresses AA and PolyI:C or LTA- induced cytokine release in pulmonary 
fibroblasts. AA is a bio-active molecule and is a precursor that is metabolized by COX to produce 
eicosanoids, including the prostaglandins (25, 34). Prostaglandins are known to play a key role in the 
generation of inflammatory responses. To investigate whether COX-mediated prostaglandins 
contribute to the induction of IL-6 and CXCL8 release, HPFs were pre-treated with the non-selective 
COX-inhibitor, indomethacin. We found that indomethacin (10-5M) pre-treatment suppressed IL-6 
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and CXCL8 release induced by AA alone (Figure 6A and 6B), AA in combination with PolyI:C (Figure 6E 
and 6F) and AA in combination with LTA (Figure 6G and 6H) (n = 9-14, p<0.01). However, 
indomethacin pre-treatment did not affect cytokine release induced by PolyI:C alone. Inhibition of 
COX and p38 MAPK were the only two pathways to inhibit both AA and PolyI:C- as well as AA and 
LTA-induced IL-6 and IL-8 release.
AA and PolyI:C or LTA-induced cytokine release in BEAS-2Bs is mainly mediated JNK and p38 MAPK 
signaling. The underlying mechanisms in BEAS-2Bs were also investigated and we found that 
phosphorylation of p38 MAP kinase was increased 30 minutes after stimulation with AA alone, and 
AA in combination with PolyI:C or LTA (n = 8, p<0.05) (Figure 7A). NF-κB phosphorylation was 
increased upon challenge with PolyI:C and LTA alone, and challenge with AA in combination PolyI:C 
(n = 7, p<0.05) (Figure 7B). Phosphorylation of SAPK/JNK was increased upon challenge with AA in 
combination with LTA (n = 7, p<0.05) (Figure 7C). 
In addition, inhibition of p38 MAP kinase or JNK suppressed IL-6 and CXCL8 release induced by 
PolyI:C alone, AA in combination with PolyI:C and AA in combination with LTA (n = 7, p<0.05) (Figure 
8). Inhibition of NF-κB suppressed IL-6 and CXCL8 release induced by AA in combination with PolyI:C 
(n = 7, p<0.05) (Figure 8A and 8B), and CXCL8 release induced by PolyI:C alone (p<0.05) (Figure 8D). 
Inhibition of JNK resulted in the greatest suppression of combined AA and PolyI:C- or LTA-induced IL-
6 and CXCL8 release. Inhibition of COX did not suppress IL-6 or CXCL8 release in BEAS-2Bs. These 
results show that the responses in BEAS2Bs are different from HPFs and are mediated through NF-
κB, JNK, p38 MAP kinase, but not COX signaling and suggest JNK signaling to be the dominant 
pathway.
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Infection with human RV16 leads to greater AA-induced cytokine release.
To ensure that our results with pathogen components are reflective of a live infection, we next 
assessed if the innate immune response to RV was modulated by AA. RV was chosen due to its high 
prevalence in the community and has been shown to be a major cause of asthma exacerbations (8). 
Challenge with AA (100µM) in combination with RV16 infection at MOI of 1.0 resulted in 
substantially greater IL-6 and CXCL8 (p<0.05) release than AA or RV alone from HPFs (n = 9) (Figure 
9A and 9B) and BEAS2Bs (n = 7) (replicates) (Figure 9C and 9D). The effect of the combination of AA 
with RV16 on IL-6 and CXCL8 release was greater than the sum of the individual effects of AA and 
RV16 in both cell types, demonstrating synergistic effects. 
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Discussion 
Obese asthma patients have more frequent and severe exacerbations, which may be a result of 
excess dietary fatty acids enhancing the innate immune response to viral and/or bacterial infection. 
This study is the first to examine the effects of dietary fatty acids in this context.
This study demonstrates that the ω-6 PUFA AA in combination with the viral mimic PolyI:C results in 
greater IL-6 and CXCL8 release than either AA or PolyI:C alone. Interestingly, the effect of the 
combination on cytokine release was substantially greater than the sum of the individual effects of 
AA and PolyI:C which indicates that these effects are synergistic. We also examined the effects of 
dietary fatty acids on respiratory infection in epithelial cells. Interestingly, we found that epithelial 
cells are unresponsive to AA alone, but the combination with PolyI:C results in synergistic cytokine 
release. In addition, PA enhanced PolyI:C-induced cytokine release from epithelial cells. These results 
show that dietary fatty acids have different effects on different lung cells and suggest that increased 
levels of AA and PA during viral infection may lead to more severe airway inflammation. 
The current study mainly focussed on the cytokines IL-6 and CXCL8, as these are crucial drivers of 
neutrophilic inflammation and are clinically important in both the pathogenesis of asthma and 
clinical outcomes in severe and obese asthma, including viral-induced exacerbations. However 
multiple cytokines and chemokines are important in driving granulocyte recruitment and activation 
in asthma. We also measured CCL5 (RANTES) and GM-CSF release. There was no induction of GM-
CSF in both cell types. However, DHA reduced PolyI:C-induced RANTES in HPFs and BEAS2Bs. In 
addition, AA reduced PolyI:C-induced RANTES in fibroblasts, but not BEAS2Bs. We interpret these 
results as further evidence that the immune response in obese asthma is skewed towards 
neutrophilic inflammation. If there was GM-CSF induction, this would have been evidence of a 
granulocytic response, since it promotes the proliferation, differentiation, and activation of 
monocytes, neutrophils, eosinophils and dendritic cells and act as a cofactor for superoxide 
production and degranulation (35, 36). The suppression of CCL5 (RANTES) by AA further reinforces 
neutrophilic inflammation as it typically recruits monocytes, T cells, and eosinophils and has been 
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associated with eosinophilic airway inflammation in asthma (37, 38). 
RV is the most common cause of virus-induced exacerbations in both children and adults with 
asthma (8, 39). In the past, RV was considered as an upper respiratory pathogen only. However, in 
vivo studies have conclusively shown that RV can also replicate in the lower airways (26, 40) and can 
infect submucosal cells which include pulmonary fibroblasts and airway smooth muscle cells. We 
(41) and others (42) have shown that RV infects primary pulmonary fibroblasts inducing pro-
inflammatory mediators including IL-6 and CXCL8 (41). Fibroblasts are located within the airway 
submucosa where airway blood vessels are found and are therefore directly exposed to constituents 
of tissue fluids (plasma) including dietary fatty acids, and are likely to be key cells in driving 
inflammatory responses to serum derived factors. As such, this study primarily focussed on 
pulmonary fibroblasts. 
Viruses activate the innate immune response through activation of the molecular pattern 
recognition TLR 3,7 and 8 (43) via the activation of specific transcription factors including NF-κB and 
AP-1. PolyI:C is a synthetic analogue of double stranded RNA (dsRNA) and is known to activate TLR3 
(44). TLR 7 and 8 detect ssRNA, while TLR 3 detects dsRNA which occurs when ssRNA viruses, 
including RV, replicate (43). We used an agonist for TLR3 rather than TLR 7 or 8 based on previous 
studies showing that RV induces cytokines via the activation of TLR3 and not TLR 7/8 in bronchial 
epithelial cells. Furthermore, we have previously shown that RV-induced cytokine release in 
fibroblasts is replication dependent (i.e the cells are detecting and responding only to dsRNA)(41).. 
To confirm that AA increases RV-induced inflammation, we also assessed the response to AA in 
combination with RV16 infection. We found that challenge with AA in combination with RV16 
infection results in substantially greater cytokine release than either AA or RV16 alone in HPFs and 
BEAS-2Bs.  
Less is known about bacterial infections in asthma. Some bacterial pathogens are more frequently 
found in the airways of patients with asthma than in healthy patients (12), but their role in 
exacerbations is unclear. Studies have reported mycoplasmal infection in up to 25% of children with 
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wheezing (11) and in 20% of asthmatic children requiring hospitalization due to exacerbations. 
However, not all studies confirm these findings (45). The current study also investigated the effect of 
dietary fatty acids on bacterial infection. To model bacterial infection, we challenged cells with the 
bacterial endotoxin LTA. We found that challenge with AA in combination with LTA results in greater 
IL-6 and CXCL8 release from pulmonary fibroblasts and epithelial cells than either alone. The effect 
of the combination on cytokine release was substantially greater than the sum of the individual 
effects of AA and LTA which indicates that these effects are synergistic. These results indicate that 
exposure to AA during bacterial infection may lead to more severe airway inflammation. There was 
no interaction between the other dietary fatty acids and LTA. Bacterial recognition is dependent on 
TLR 2 and 4. TLR4 mainly senses lipopolysaccharide (LPS), which is a major component of the outer 
membrane of gram-negative bacteria. TLR2 is the primary innate immune receptor for gram-positive 
bacteria. We used LTA, an important cell wall polymer found in gram-positive bacteria that has been 
shown to cause innate immune responses mediated through TLR2 (46).
LTA alone however, did not induce cytokine release from either HPFs or BEAS2Bs. Presumably, even 
though bronchial epithelial cells express toll like receptor (TLR)2, challenge with LTA is not potent 
enough to induce the production of IL-6 or CXCL8 in epithelial cells and a co-challenge is needed. 
Other studies have reported similar findings. Amstrong et al. (2004) found that LTA alone does not 
induce the production of CXCL8 or IL-6 (47) in bronchial epithelial cells and a low responsiveness of 
lung epithelial cells to LTA (small increase in CXCL8 release) was observed in another in vitro study 
(48).
Effects of dietary fatty acids on immune responses have been an area of interest for many years. 
However, there is a great deal of conflicting data. DHA and AA serve as important cell membrane 
components as well as precursors for biologic mediators with many effects, including numerous 
roles in immune function and inflammation. In general, ω-6 PUFAs and SFAs have predominantly 
been associated with pro-inflammatory effects, whereas the ω-3 PUFAs are associated with anti-
inflammatory and immunosuppressive effects (25, 34). None of the ω-3 PUFAs (DHA, EPA and ALA) 
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suppressed PolyI:C-induced cytokine release, or combined AA and PolyI:C-induced inflammatory 
responses in HPFs, suggesting that ω-3 PUFAs do not have anti-inflammatory effects in these lung 
cells. SFAs including PA initiate innate immune responses through activation of TLR2 and 4 in 
adipocytes and macrophages (24, 49, 50). These results have been replicated in human studies 
where within 4 hours of consumption of a high fat meal, innate immune responses are activated 
with increased TLR2, -4 and NF-κB activity in mononuclear and polymorphonuclear cells (51, 52). The 
non-responsiveness to PA in this study may be explained by the lack of functional TLR4 signaling in 
pulmonary fibroblasts. Lung mesenchymal cells do not express CD14, which acts as a co-receptor for 
TLR4 (53, 54). This is also the reason why we used LTA (TLR2 agonist) and not LPS (TLR4 agonist). 
SFAs have been shown to inhibit virus replication in a mouse model of chronic hepatitis B infection 
(55), however another mouse model study showed that SFAs increase bacterial load in S. aureus 
infection (56). Studies looking at effects of ω-6 PUFAs on inflammatory processes and infections 
have found conflicting data. A study in healthy men found that supplementation with ω-6 PUFAs 
significantly increased the number of circulating neutrophils and production of LPS-induced 
leukotriene B4 from leukocytes. Conversely, supplementation with AA did not affect in vitro 
secretion of TNFα by peripheral mononuclear cells, nor did it affect peripheral blood mononuclear 
cell proliferation and natural killer cell activity (57). A study by Jordao et al. (2008) found that AA 
enhanced bacterial killing of Mycobacterium tuberculosis in macrophages, but increased pathogen 
survival in a mouse model of tuberculosis (58). In the current study a clear pro-inflammatory effect 
of AA on bacterial and viral infection was observed. 
To understand the underlying mechanisms involved in (synergistic) AA and PolyI:C- or LTA-induced 
IL-6 and CXCL8 production, signaling pathways were investigated. We observed activation of p38 
MAPK upon challenge with AA alone and in combination with PolyI:C or LTA. Challenge with PolyI:C 
and LTA alone led to increased phosphorylation of NF-κB, while challenge with the combination of 
AA and PolyI:C caused increased phosphorylation of SAPK/JNK. AA in combination with PolyI:C led to 
greater phosphorylation of p38 MAP kinase than challenge with AA alone, indicating p38 MAP kinase 
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signaling to be the mechanism by which synergism occurs. We further investigated and confirmed 
the underlying mechanisms involved in AA and PolyI:C- or LTA-induced IL-6 and CXCL8 release using 
specific signaling inhibitors at concentrations previously shown to be effective in human airway cells 
(26-28). SB239063 is a potent and selective inhibitor of p38 MAP kinase and displays specific and 
high-affinity binding (IC50 = 44nM) (59). It suppressed IL-6 and CXLC8 release induced by AA alone 
and the combinations of AA and PolyI:C or LTA. These data suggest that AA in combination with 
PolyI:C or LTA activates the p38 MAPK pathway, leading to both IL-6 and CXCL8 release. Inhibition of 
JNK with SP600125 suppressed IL-6 release induced by PolyI:C alone and in combination with AA, but 
did not affect CXCL8 release. Inhibition of NF-κB with BAY- 117082 partially suppressed IL-6 release 
induced by the combination of AA and LTA, again indicating the involvement of multiple pathways. 
These results, which showed that BAY-117082 suppressed AA and LTA-induced IL-6 but not CXCL8 
release while SP600125 suppressed PolyI:C- and AA/PolyI:C-induced IL-6 but not CXCL8 release, are 
unexpected. Previous studies have shown IL-6 and CXCL8 transcription to be regulated by the same 
transcription factors: NF-κB, CREB protein, AP-1, and CCAAT/enhancer binding protein (C/EBP) (60, 
61). However, it appears that in this study the dominant transcription factors regulating CXCL8 are 
different to those regulating IL-6 with p38 MAPK being the only common transcription factor for 
both cytokines. 
Prostaglandins (PGs), including PGE2, are COX metabolites of arachidonic acid. PGE2 induces IL-6 
release from bronchial epithelial cells and CXCL8 from lung mesenchymal cells (62, 63). To 
investigate whether COX-mediated prostaglandins contribute to IL-6 and CXCL8 release, we pre-
treated pulmonary fibroblasts with indomethacin, which inhibits both COX-1 and COX-2. 
Indomethacin inhibited AA-induced IL-6 and CXCL8 release alone and in combination with PolyI:C or 
LTA. However, indomethacin did not affect cytokine release induced by PolyI:C alone. Our data 
suggest that IL-6 and CXCL8 production in HPFs is prostaglandin-mediated. We consider these effects 
to be mediated through COX-2 rather than COX-1, as COX-1 is responsible for constitutive 
production under basal conditions, whereas COX-2 is upregulated during inflammation and is 
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responsible for PGE2 biosynthesis at sites of inflammation (64). We consider the combination of the 
production of COX-mediated prostaglandins and the activation of transcription factors the most 
logical mechanism for synergistic cytokine release in HPFs.
We also investigated the underlying mechanisms in BEAS-2Bs and found that p38 MAP kinase 
signaling is involved in PolyI:C-, combined PolyI:C and AA- and combined LTA and AA-induced IL-6 
and CXCL8 release in BEAS-2Bs. However, inhibition of COX did not suppress IL-6 or CXCL8 release in 
BEAS-2Bs, which is different from what we observed in fibroblasts. This is consistent with the lack of 
cytokine induction by AA in BEAS-2B. In addition, inhibition of JNK signaling resulted in the greatest 
suppression of combined AA and PolyI:C- or LTA-induced IL-6 and CXCL8 release in BEAS-2BS. These 
results suggest that there is a differential response in BEAS-2Bs compared to fibroblasts. Although 
the studies in this manuscript utilized primary human pulmonary fibroblasts, an important limitation 
of this study is that all studies were done in vitro. In future studies effects of dietary fatty acids on 
immune responses to infection will be investigated using an in vivo model.
In summary, this study demonstrates that exposure of HPFs and epithelial cells to ω-6 PUFAs causes 
an amplification of the inflammatory responses to viral and bacterial components, as measured by 
IL-6 and CXCL8 release. In HPFs the responses were prostaglandin dependent and mediated through 
p38 MAP kinase signaling, whereas the responses in BEAS-2Bs were mainly mediated through JNK 
and p38 MAP kinase signaling, suggesting that p38 MAPK inhibitors might be effective in obese 
asthmatics to prevent exacerbations. In epithelial cells exposure to PA also enhances the 
inflammatory response to viral infection. These results suggest that during respiratory infection, 
increased levels of dietary ω-6 PUFAs and SFAs may lead to more severe airway inflammation and 
might contribute to and/or increase the severity of asthma exacerbations in obese asthma patients. 
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Table 1. Summary of patient demographics
BOS: Bronchiolitis obliterans syndrome, COPD: chronic obstructive pulmonary disease, Adeno ca: 
adenocarcinoma, NSCLC: non-small cell lung carcinoma, PAH: pulmonary arterial hypertension, IPF: idiopathic 
pulmonary fibrosis, F: Female, M: Male
Donor # Diagnosis Age Gender Surgery  Experiment 
1 Emphysema 61 F explanted lung fatty acids and bacterial/viral mimics 
3 BOS 43 M explanted lung fatty acids and bacterial/viral mimics
4 COPD 60 F explanted lung fatty acids and bacterial/viral mimics
5 NSCLC 62 F lung resection fatty acids and bacterial/viral mimics
6 Ca adeno 60 F lung resection fatty acids and bacterial/viral mimics
7 Emphysema 65 F explanted lung fatty acids and bacterial/viral mimics
8 Healthy 65 M explanted lung fatty acids and bacterial/viral mimics
9 Healthy 41 F explanted lung fatty acids and bacterial/viral mimics
10 COPD 65 M explanted lung fatty acids and bacterial/viral mimics
11 Adeno ca 72 F lung resection fatty acids and bacterial/viral mimics
12 COPD 61 F explanted lung western blotting, inhibitors, 
fatty acids and bacterial/viral mimics
13 COPD 62 F explanted lung western blotting, inhibitors
14 Emphysema 65 F explanted lung western blotting, Inhibitors
15 Adeno ca 57 F lung resection western blotting, inhibitors
16 PAH 57 F explanted lung western blotting, inhibitors 
17 IPF 67 M explanted lung western blotting
18 Adeno ca 76 F lung resection western blotting, inhibitors, RV16 infection
19 Adeno ca 64 F lung resection western blotting, inhibitors, RV16 infection
20 IPF 63 M explanted lung western blotting, inhibitors, RV16 infection
21 Emphysema 59 M explanted lung western blotting, inhibitors, RV16 infection
22 PAH 57 F explanted lung western blotting, inhibitors, RV16 infection
23 COPD 62 F explanted lung western blotting, inhibitors, RV16 infection
24 PAH 30 F explanted lung western blotting, inhibitors, RV16 infection
25 Emphysema 62 F explanted lung Inhibitors
26 Emphysema 59 M explanted lung Inhibitors
27 COPD 56 F explanted lung inhibitors
28 IPF 58 F explanted lung inhibitors
29 Emphysema 64 M explanted lung inhibitors
30 NSCLC, COPD 58 M lung resection inhibitors
31 IPF 64 M explanted lung inhibitors, RV16 infection
32 Emphysema 61 M explanted lung inhibitors, RV16 infection 
33 COPD 69 F explanted lung mixed ω-6:ω-3 PUFAs, ALA and EPA 
34 Interstitial pneumonitis 59 M explanted lung mixed ω-6:ω-3 PUFAs, ALA and EPA
35 IPF 64 M explanted lung mixed ω-6:ω-3 PUFAs, ALA and EPA
36 NSCLC 71 F lung resection mixed ω-6:ω-3 PUFAs, ALA and EPA
37 Adeno ca and COPD 75 F lung resection mixed ω-6:ω-3 PUFAs, ALA and EPA
38 IPF 63 F explanted lung mixed ω-6:ω-3 PUFAs, ALA and EPA
39 Squamous cell ca 65 M lung resection mixed ω-6:ω-3 PUFAs, ALA and EPA
40 Adeno ca 72 F lung resection mixed ω-6:ω-3 PUFAs, ALA and EPA
41 IPF 54 M explanted lung mixed ω-6:ω-3 PUFAs, ALA and EPA
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Figure legends
Figure 1. Greater cytokine release with combined arachidonic acid and PolyI:C challenge, than 
either aloneHuman primary pulmonary fibroblasts were unstimulated or challenged with ω-6 
polyunsaturated fatty acid (PUFA) arachidonic acid (AA) (n = 8-11) (patients) (A-C), ω-3 PUFA 
docosahexaenoic acid (DHA), (n = 5-9) (patients) (D-F) or saturated fatty acid (SFA) palmitic acid (PA), 
(n = 3-9) (patients) (G-I) in 0.1% BSA-DMEM (100μM) for 4h with or without the viral mimic 
polyinosinic:polycytidylic acid (PolyI:C) (10µg/ml) for another 24h. Cell free supernatants were 
collected and IL-6 (A, D, G), CXCL8 (B, E, H) or CCL5 (C, F, I) release was measured using ELISA. All 
data are represented as mean ± standard error of the mean. All challenges are compared to control 
and challenges with PolyI:C are compared to their respective challenge without PolyI:C and challenge 
with PolyI:C alone, using a one-way ANOVA with a Bonferroni post-test. Significance is represented 
as * (p<0.05), ** (p<0.01), *** (p<0.001) or **** (p<0.0001). 
Figure 2. Greater cytokine release with combined arachidonic acid and LTA challenge, than either 
alone in Human primary pulmonary fibroblasts were unstimulated (control) or challenged with ω-6 
polyunsaturated fatty acid (PUFA) arachidonic acid (AA), (n = 11) (patients) (A, B), ω-3 PUFA 
docosahexaenoic acid (DHA), (n = 10) (patients) (C, D) or saturated fatty acid (SFA) palmitic acid (PA), 
(n = 9) (patients) (E, F) in 0.1% BSA-DMEM (100μM) for 4h prior with or without  the bacterial 
compound lipoteichoic acid (LTA) (10µg/ml) for another 24h. Cell free supernatants were collected 
and IL-6 (A, C, E) and CXCL8 (B, D, F) release was measured using ELISA. All data are represented as 
mean ± standard error of the mean. All challenges are compared to control and challenges with LTA 
are compared to their respective challenge without LTA and challenge with LTA alone, using a one-
way ANOVA with a Bonferroni post-test. Significance is represented as * (p<0.05) or *** (p<0.001).
Figure 3. Greater IL-6 release with combined arachidonic acid or palmitic acid and PolyI:C 
challenge than either alone in BEAS-2Bs. The human bronchial epithelial cell line BEAS-2B was 
unstimulated (control) or challenged with ω-6 polyunsaturated fatty acid (PUFA) arachidonic acid 
(AA) (n = 6-7) (replicates) (A-C), ω-3 PUFA docosahexaenoic acid (DHA) (n = 6-7) (replicates) (D-F) or 
saturated fatty acid (SFA) palmitic acid (PA) (n = 6-7) (replicates) (G-I) in 0.1% BSA-DMEM (100μM) 
for 4h prior with or without the viral mimic polyinosinic:polycytidylic acid (PolyI:C) (10µg/ml) for 
another 24h. Cell free supernatants were collected and IL-6 (A, D, G), CXCL8 (B, E, H) and CCL5 (C, F, 
I) release was measured using ELISA. All data are represented as mean ± standard error of the mean. 
All challenges are compared to control and challenges with PolyI:C are compared to their respective 
challenge without PolyI:C and challenge with PolyI:C alone, using a one-way ANOVA with a 
Bonferroni post-test. Significance is represented as * (p<0.05), ** (p<0.01) or *** (p<0.001).
Page 23 of 43  AJRCMB Articles in Press. Published on 16-January-2019 as 10.1165/rcmb.2018-0215OC 
 Copyright © 2019 by the American Thoracic Society 
Figure 4. Greater cytokine release with combined arachidonic acid and LTA challenge, than either 
alone in BEAS-2Bs. The human bronchial epithelial cell line BEAS-2B was unstimulated (control) or 
challenged with ω-6 polyunsaturated fatty acid (PUFA) arachidonic acid (AA) (n = 6) (replicates) (A,B), 
ω-3 PUFA docosahexaenoic acid (DHA) (n = 6) (replicates) (C, D) or saturated fatty acid (SFA) palmitic 
acid (PA) (n = 6) (replicates) (E, F) in 0.1% BSA-DMEM (100μM) for 4h prior with or without the 
bacterial compound lipoteichoic acid (LTA) (10µg/ml) for another 24h. Cell free supernatants were 
collected and IL-6 (A, C, E) and CXCL8 (B, D, F) release was measured using ELISA. All data are 
represented as mean ± standard error of the mean. All challenges are compared to control and 
challenges with LTA are compared to their respective challenge without LTA and challenge with LTA 
alone, using a one-way ANOVA with a Bonferroni post-test. Significance is represented as * (p<0.05) 
or ** (p<0.01). 
Figure 5. Activation of p38 MAP kinase, NF-κB and SAPK/JNK upon challenge with AA and PolyI:C 
or LTA. Primary human pulmonary fibroblasts (n = 7-8) (patients) were unstimulated (control) or 
challenged with arachidonic acid (AA) (100μM), the viral mimic polyinosinic:polycytidylic acid 
(PolyI:C) (10µg/ml), the bacterial compound lipoteichoic acid (LTA) (10µg/ml), AA (100μM) in 
combination with (PolyI:C) (1ng/mL) or AA (100µ) in combination with LTA for 30 minutes, before 
whole cell lysates were collected and p38 mitogen-activated protein (MAP) kinase (A), NF-κB p65 (B) 
or JNK (C) phosphorylation was assessed by western blotting. Total p38 MAP kinase (D), NF-κB p65 
(E) or JNK (F) was also assessed. All values were normalized to GAPDH (housekeeping protein), 
detected on the same blots. Data are expressed as fold increase of control, mean ± standard error of 
the mean. All challenges are compared to control and challenges with PolyI:C or LTA are compared 
to their respective challenge without PolyI:C or LTA and challenge with PolyI:C or LTA alone, using a 
one-way ANOVA (Fisher’s LSD test). Significance is represented as *(p<0.05), ** (p<0.01), *** 
(p<0.001) or **** (p<0.0001). Representative western blots of phosphorylated and total p38 MAPK, 
NF-κB p65 and JNK are shown under each graph.
Figure 6. Inhibition of cyclooxygenase (COX) or p38 MAPK suppresses cytokine release, induced 
arachidonic acid alone and in combination with viral or bacterial surrogates from fibroblasts. 
Primary human pulmonary fibroblasts (n = 9-14) (patients) were treated with or without the 
cyclooxygenase (COX) inhibitor indomethacin (10-5M), the p38 mitogen-activated protein (MAP) 
kinase signaling inhibitor SB239063 (3μM), the NF-κB inhibitor BAY-117082 (1μM) or the c-Jun N-
terminal kinase (JNK) inhibitor SP600125 (10μM) for 60 minutes before challenge with arachidonic 
acid (AA) (100μM) (A, B), the viral mimic polyinosinic:polycytidylic acid (PolyI:C) (10µg/ml) (C, D), AA 
(100μM) in combination with PolyI:C (E, F) or AA (100µM) in combination with LTA (10µg/mL) (G, H). 
Cell free supernatants were collected after 24h and IL-6 (A, C, E, G) and CXCL8 (B, D, F, H) release 
was measured using ELISA. All data are represented % cytokine release ± standard error of the 
mean. All treatments with inhibitor are compared to their respective control in the absence of the 
inhibitor using one-way ANOVA with a Bonferroni post-test. Significance is represented as ** 
(p<0.01), *** (p<0.001) or **** (p<0.0001). 
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Figure 7. Activation of p38 MAP kinase, NF-κB and SAPK/JNK upon challenge with AA and PolyI:C 
or LTA in BEAS-2Bs. The human bronchial epithelial cell line BEAS-2B (n = 4-8) (replicates) was 
unstimulated or challenged with arachidonic acid (AA) (100μM), the viral mimic 
polyinosinic:polycytidylic acid (PolyI:C) (10µg/ml), the bacterial compound lipoteichoic acid (LTA) 
(10µg/ml), AA (100μM) in combination with (PolyI:C) (1ng/mL) or AA (100µM) in combination with 
LTA for 30 minutes, before whole cell lysates were collected and p38 mitogen-activated protein 
(MAP) kinase (A), NF-κB p65 (B) or JNK (C) phosphorylation was assessed by western blotting. Total 
p38 MAP kinase (D), NF-κB p65 (E) or JNK (F) was also assessed. All values were normalized to 
GAPDH (housekeeping protein), detected on the same blots. Data are expressed as fold increase of 
control, mean ± standard error of the mean. All challenges are compared to control and challenges 
with PolyI:C or LTA are compared to their respective challenge without PolyI:C or LTA and challenge 
with PolyI:C or LTA alone, using a one-way ANOVA (Fisher’s LSD test). Significance is represented as 
*(p<0.05) or ** (p<0.01). Representative western blots of phosphorylated and total p38 MAPK, NF-
κB p65 and JNK are shown under each graph.
Figure 8. Inhibition p38 MAPK or JNK suppresses cytokine release, induced by AA in combination 
with PolyI:C or LTA from BEAS-2Bs. The human bronchial epithelial cell line BEAS-2B (n = 7) 
(replicates) was treated with or without the cyclooxygenase (COX) inhibitor indomethacin (10-5M), 
the p38 mitogen-activated protein (MAP) kinase signaling inhibitor SB239063 (3μM), the NF-κB 
inhibitor BAY-117082 (1μM) or the c-Jun N-terminal kinase (JNK) inhibitor SP600125 (10μM) for 60 
minutes before challenge with AA (100μM) in combination with the viral mimic PolyI:C (A, B), PolyI:C 
alone (C, D) or AA (100µM) in combination with LTA (10µg/mL) (E, F). Cell free supernatants were 
collected after 24h and IL-6 (A, C, E) and CXCL8 (B, D, F) release was measured using ELISA. All data 
are represented as % cytokine release ± standard error of the mean. All treatments with inhibitor are 
compared to their respective control in the absence of the inhibitor using one-way ANOVA with a 
Bonferroni post-test. Significance is represented as *(p<0.05) and ** (p<0.01) or *** (p<0.001) or 
**** (p<0.0001).
Figure 9. Greater cytokine release with combined arachidonic acid and human rhinovirus 16 
challenge, than either alone in human pulmonary fibroblasts and BEAS-2Bs. Human primary 
pulmonary fibroblasts (n = 9) (patients) (A, B) or BEAS-2Bs (n = 7) (replicates) (C, D) were 
unstimulated (control) or challenged with arachidonic acid (AA) in 0.1% BSA-DMEM (100μM) for 4h 
prior to infection with human rhinovirus serotype-16 (RV16) at a multiplicity of infection (MOI) of 1 
for another 24h. Cell free supernatants were collected and IL-6 (A, C) and CXCL8 (B, D) release was 
measured using ELISA. All data are represented as mean ± standard error of the mean. All challenges 
RV16 are compared to their respective challenge without RV16 and RV16 alone, using a one-way 
ANOVA with a Bonferroni post-test. Significance is represented as * (p<0.05), ** (p<0.01) or *** 
(p<0.001).
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Figure 5
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Figure 7
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ONLINE SUPPLEMENT
Dietary fatty acids amplify inflammatory responses to infection through p38 MAP 
kinase signaling
Sandra Rutting, Razia Zakarya, Jack Bozier, Dia Xenaki, Jay C. Horvat, Lisa G. Wood, 
Philip M. Hansbro, Brian G. Oliver
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Supplementary Methods 
Cell culture HPFs and BEAS-2Bs
HPFs were seeded in 12-well plates at a density of 6.2 x 104 cells/mL in DMEM containing 5% fetal 
bovine serum (FBS) and 1% Antibiotic-Antimycotic (Gibco, Grand Island, New York, US) and grown to 
sub confluence (3 days). The human bronchial epithelial cell line BEAS-2B was maintained in 10% FBS 
and 1% Antibiotic-Antimycotic in DMEM. BEAS-2Bs were seeded at a density of 1 x 105cells/mL in 12-
well plates and grown for 24 hours. Both cell types were quiesced for 24 hours prior to stimulation, 
by incubation in DMEM supplemented with 0.1% bovine serum albumin (BSA) (Sigma Aldrich, Castle 
Hill, NSW, Australia) and 1% Antibiotic-Antimycotic. All experiments were carried out using 
fibroblasts between passage 2 and 6.
Western blotting
To investigate the cell signalling pathways activated after challenge with the combinations of AA and 
POLYI:C or LTA, relative levels of phosphorylated p38 mitogen-activated protein (MAP) kinase, NF-κB 
and stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) from cell lysates were 
assessed by western blotting. Cells cultured in the presence or absence of AA (100µM) with or 
without POLYI:C (10μg/ml) or LTA (10µg/ml) for 30 min were lysed (20mM Tris, pH 7.4, 150mM NaCl, 
1mM Na2EDTA, 1mM EGTA, 20mM NA4P2P7, 2mM Na3VO4, 1% Triton X- 100, 10% glycerol, 0.1% SDS, 
0.5% sodium deoxycholate, 1% protease inhibitor cocktail set III (Millipore, USA) and 1mM 
phenylmethylsulfonyl fluoride (PMSF) (Amresco, Solon, OH, USA)). Cell lysates were separated by 
SDS/polyacrylamide gel electrophoresis (SDS-PAGE) on 10% gels and transferred to polyvinylidene 
difluoride (PVDF) membranes using a Trans-Blot Turbo transfer system (Bio-Rad). The membranes 
were incubated with rabbit anti-phospho p38 MAP kinase, rabbit anti-p38 MAP kinase, rabbit anti-
phospho NF-κB p65, rabbit anti-NF-κB p65, rabbit anti-phospho SAPK/JNK, rabbit anti-SAPK/JNK 
(1:1000, Cell Signaling Technology) or mouse anti-glyceraldehyde-3-phosphate dehydrogenase
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(GAPDH) (1:5000, Merck Millipore, USA) overnight at 4°C. After washing with Tris-buffered saline-
containing Tween 20 (0.05%), bound antibody was visualized using horseradish peroxidase-
conjugated goat anti-rabbit IgG or horseradish peroxidase-conjugated anti-mouse IgG antibody 
(Dako, USA) and enhanced chemiluminescence, and imaged (Image Station 4000MM; Kodak Digital 
Science, New Haven, CT). GAPDH served as the control.
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Supplementary Figure 1  
ω-3 PUFAs do not suppress POLYI:C-induced IL-6 and CXCL8 release.
Human primary pulmonary fibroblasts (n = 5-9) (patients) were unstimulated or challenged with ω-3 
polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) (A, B) or α-linolenic acid (ALA) (C, D) 
in 0.1% BSA-DMEM (100μM) for 4h with or without the viral mimic polyinosinic:polycytidylic acid 
(POLYI:C) (10µg/ml) for another 24h. Cell free supernatants were collected and IL-6 (A, C) and CXCL8 
(B, D) release was measured using ELISA. All data are represented as mean ± standard error of the 
mean. All challenges are compared to control and challenges with POLYI:C are compared to 
challenge with POLYI:C alone, using a one-way ANOVA with a Bonferroni post-test. Significance is 
represented as * (p<0.05), ** (p<0.01), *** (p<0.001) or **** (p<0.0001).
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Supplementary Figure 2  
 
ω-3 PUFAs do not suppress combined arachidonic acid and POLYI:C-induced IL-6 or CXCL8 release. 
Human primary pulmonary fibroblasts (n = 9) (patients) were challenged with ω-6 polyunsaturated 
fatty acid (PUFA) arachidonic (AA) (100µM) with or without ω-3 PUFAs docosahexaenoic acid (DHA) 
(25µM), eicosapentaenoic acid (EPA) (25µM) or α-linolenic acid (ALA) (25µM) in 0.1% BSA-DMEM for 
4 hours prior to challenge with the viral mimic polyinosinic:polycytidylic acid (POLYI:C) (10µg/ml) for 
another 24h. Cell free supernatants were collected and IL-6 (A) and CXCL8 (B) release was measured 
using ELISA. All data are represented as mean ± standard error of the mean. All challenges with ω-3 
PUFA are compared to their respective challenge without ω-3 PUFA, using a one-way ANOVA with a 
Bonferroni post-test. There were no significant differences. 
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